Vertex Pharmaceuticals: A Long-Term Owner's View

Hunting ten-year five-baggers among great growth stocks — pressing the upside question: "Can it get much bigger?"

• QHow large is its market ceiling? Is it expanding an existing pie, or creating an entirely new market?5/10

  A

  Both, but the weight is very uneven: more than 90% of today's ceiling still comes from pushing the existing cystic fibrosis pie to its limit, while the parts that are genuinely "creating new markets" (CASGEVY's genetic cure and JOURNAVX's non-opioid pain treatment) are real directions with substantial optionality, but for now they remain rounding errors on the income statement. When Baillie Gifford asks about the ceiling, the real question is whether this lane can hold a 5x increase over ten years. For Vertex, the answer depends heavily on whether it can turn the latter from story into cash flow.

  Start with the existing pie. CF is a niche market Vertex has already nearly monopolized and continues to expand on its own: the report discloses 2025 TRIKAFTA/KAFTRIO revenue of about 10.313 billion dollars, with the CF franchise contributing about 98.5% of product revenue. The logic for "expanding" this market is not share gain (it has almost no rivals), but covering as many treatable mutation groups as possible and then using ALYFTREK as an internal upgrade. The report says ALYFTREK covers 31 more responsive mutations than the prior generation. That also defines the shape of the ceiling: CF is an installed market with a limited patient population and very deep Vertex penetration. It can provide extremely stable cash flow, but it is hard for it alone to support a "5x in ten years" expansion in scale.

  The real "new market creation" sits in two areas. The first is CASGEVY, a one-time gene-editing therapy for sickle cell disease and transfusion-dependent beta thalassemia. It is effectively creating the formerly nonexistent category of a "functional cure." The second is JOURNAVX (suzetrigine), which the report describes as the first FDA-approved non-opioid oral pain signal inhibitor and the first new-mechanism pain medicine in more than 20 years; the company estimates the U.S. acute pain prescription market covers more than 80 million people each year. This is a theoretically very large TAM, but penetration must be built from zero.

  Whether the ceiling is high depends on whether the new markets can be "opened," not merely whether they "exist." The evidence is mixed: Vertex's 2026 full-year guidance is total revenue of 12.95 billion to 13.10 billion dollars and non-CF revenue of at least 500 million dollars, showing that the new markets are still just starting and remain a single-digit share; yet CASGEVY and JOURNAVX together contributed more than 25% of first-quarter 2026 growth, showing that incremental growth has already begun to tilt toward new markets. The problem is that the "opening cost" of the ceiling is high: the report notes that globally in 2025 only about 300 people started CASGEVY treatment, 147 completed first cell collection, and 64 completed infusion (a pace consistent with publicly disclosed full-year patient data). The bottleneck is not efficacy, but manufacturing, the treatment-center network, patient screening, and payment coverage.

  Conclusion: as the "dominant player in an existing pie," Vertex's ceiling is stable but limited; as a "creator of new markets," its potential ceiling is high but still far from proven reachable. An honest judgment is that the ceiling that can be established today is mainly defined by the mature CF pie; the new markets are call options, not territory already captured.

  Jun 10, 2026
• QCan its revenue at least double over the next five years? Will growth mainly be driven by volume, price, or new businesses?4/10

  A

  Conclusion: a revenue "doubling" over the next five years (from about 12 billion dollars in 2025 to about 24 billion dollars) is optimistic and not the base case; the near-term growth implied by the company's own guidance is far below the pace required for a doubling. Whether it can get close depends almost entirely on whether the new businesses (gene therapy + non-opioid pain treatment + kidney disease) can all scale at the same time, not on CF volume or price.

  First anchor the starting point using the company's own numbers. Vertex's 2026 full-year revenue guidance is 12.95 billion to 13.10 billion dollars, implying about 8%-9% growth versus the roughly 12 billion dollar midpoint for 2025; first-quarter 2026 revenue was about 2.99 billion dollars, up about 8% year over year. Doubling in five years requires a roughly 15% compound annual growth rate sustained for five years, almost twice the current guided growth rate. So "doubling" is not what one gets from a straight-line extrapolation; it requires a meaningful acceleration in the growth curve.

  Now separate the three drivers and ask whether each is enough:

  First, price: resilient, but not the main engine. The report notes that the company attributed part of U.S. revenue growth in 2025 and the first quarter of 2026 to higher realized net prices, and CF does have pricing power. But specialty-drug price increases are constrained by payers, PBMs, and government pricing. Long-term revenue doubling driven by price increases alone is neither realistic nor healthy. Price is more like a way to protect the base and add single-digit incremental growth.

  Second, volume: CF has limited room for volume growth. CF is an installed market where Vertex already has deep penetration. ALYFTREK is mainly an internal replacement and upgrade for TRIKAFTA rather than a source of net new patients. The report says the CF franchise accounted for about 98.5% of product revenue in 2025, but year-over-year growth has already started to plateau (TRIKAFTA/KAFTRIO went from 10.239 billion in 2024 to 10.313 billion in 2025, nearly flat). There is not enough patient base for CF volume to double total revenue.

  Third, new businesses: this is the only plausible source of a doubling, but visibility is low. The company's 2026 non-CF revenue guidance is only "at least 500 million dollars", still a rounding error against a 13 billion total base. Supporting a doubling would mean JOURNAVX must grow from the report's 2025 figure of 60 million dollars into a multi-billion-dollar product, CASGEVY must break through manufacturing and treatment-center bottlenecks to scale meaningfully (report: only 64 people completed infusion in 2025), and kidney-disease programs such as povetacicept must successfully launch. That is a combination of several independent bets all needing to land. No single one is certain enough on its own.

  From Baillie Gifford's growth lens, the most likely base case over the next five years is solid growth but short of a doubling (the report's neutral intrinsic value case implies about 6% ten-year growth). Doubling belongs to the optimistic tail. The "quality" of the growth would be attractive if it happens: it would be driven by new businesses, mainly volume, with an improving revenue mix, which is far healthier than relying on price to support the numbers. But the answer to "can it" today is only: there is a path, but no assurance.

  Jun 10, 2026
• QFive years from now, what will take over as the next growth engine? Does this "second curve" exist today?5/10

  A

  Conclusion: the second curve "already exists, but is not yet load-bearing." The candidates are clear: non-opioid pain treatment (the JOURNAVX/suzetrigine series), genetic cures (CASGEVY), kidney disease (povetacicept, inaxaplin), and more distant type 1 diabetes (zimislecel). These are marketed products or late-stage pipelines, not PPT slides. But as of the first quarter of 2026, they still contributed only about 2.4% of product revenue combined, so the "handoff" remains in the early execution stage. What Baillie Gifford values most is whether the second curve already exists; on that point Vertex answers well. The harder question is the probability that it can take over enough weight to reset the revenue structure.

  Look at the quality of each candidate:

  JOURNAVX (acute pain, non-opioid): the strongest potential "new market creation" candidate. The report describes it as the first FDA-approved non-opioid oral pain signal inhibitor, targeting a U.S. acute pain prescription market the company estimates at more than 80 million people per year. By the end of 2025 it had secured the three major national PBMs, and in the first quarter of 2026 about 240 million people had reimbursement access. Its ceiling is the highest, but turning "coverage" into "volume" requires proof that it can keep penetrating at prices far above generic opioids/NSAIDs.

  CASGEVY (SCD/TDT genetic cure): the strongest clinical value, the hardest commercial slope. It is creating the new category of a "functional cure," but the report notes that globally in 2025 only about 300 people started treatment, 147 completed first cell collection, and 64 completed infusion (consistent with public patient data). The bottlenecks are the complexity of manufacturing, treatment centers, patient screening, and payment coverage. This is a curve with high efficacy certainty and a low scaling slope.

  Kidney disease (povetacicept, inaxaplin): structurally the most important. The report says Vertex acquired Alpine for about 4.9 billion dollars in equity value in 2024 to obtain povetacicept, alongside internally developed inaxaplin (APOL1 kidney disease). The direction is to reinvest CF cash flow into a real large disease category. This is the company's bet on a "second pillar," but clinical and regulatory uncertainty is meaningfully higher than in CF.

  The near-term signals are mixed: on one hand, CASGEVY and JOURNAVX together contributed more than 25% of first-quarter 2026 growth, showing that incremental growth is indeed beginning to come from the second curve; on the other hand, the company's 2026 non-CF revenue guidance is only "at least 500 million dollars", still a single-digit share against a roughly 13 billion dollar total base. The report itself also admits that "diversification remains a direction, not a reality," and states that CF still accounted for about 97.6% of product revenue in the first quarter of 2026.

  My judgment: the second curve really does "exist today," and it is a portfolio rather than a single bet (pain + gene + kidney disease + T1D). That reduces the probability of total failure and makes Vertex steadier than a single-product biotech. But it is not yet possible to name which one will become the main engine five years from now. More likely, several curves will each contribute part of the answer and together slowly pull CF down from about 98% of revenue, rather than one quickly growing into a second 10 billion dollar franchise. From Baillie Gifford's perspective, this is a set of call options that has been lit, with the slope still to be proven.

  Jun 10, 2026
• QWhat is its core competitive advantage? Will this moat widen or narrow over the next three to five years?6/10

  A

  Conclusion: the core moat is "patent/regulatory exclusivity + first-mover advantage and expertise in specific disease areas + the continuous innovation capacity supported by high-margin cash flow." Over the next three to five years, the moat within CF will probably hold or even widen slightly; but whether the company-level moat widens or narrows depends on whether the non-CF businesses can replicate this capability in kidney disease, pain treatment, and gene therapy. That has not yet been proven, so the direction of the overall company moat is still "undetermined."

  Start with the real sources of the moat, in order of strength:

  The hardest layer is patent and regulatory exclusivity. The report discloses that the basic U.S. and European patents for TRIKAFTA/KAFTRIO are expected to expire in 2037, ALYFTREK in 2039, JOURNAVX in 2040, and CASGEVY's U.S. regulatory exclusivity in 2035. This means the core cash flows have legal protection for more than another decade, and competitors cannot simply copy them.

  Next is disease-area expertise and switching costs. CF is a moat Vertex built through serial innovation, developing multiple generations of products in the same disease. Physicians, patients, and payers are deeply conditioned around Vertex, and the main competition comes from Vertex "replacing itself" (ALYFTREK upgrading TRIKAFTA). For specialty chronic medicines, unless an overwhelmingly superior therapy appears, willingness to switch is limited. That creates moderately strong switching costs.

  Third is capital and scale. This point is often underestimated: high gross margin (about 86.2% in 2025 under the report's metric, consistent with public statements showing 86%+ gross margin) plus a large net cash position (report: about 12.997 billion dollars in cash and marketable securities in the first quarter of 2026, with no material interest-bearing debt) allow Vertex to absorb R&D failures inside the system. The report cites examples: in 2025 the failure of VX-264 led to a 379 million dollar impairment, and in 2024 the Alpine acquisition created about 4.4 billion dollars of AIPR&D expense. The company could bear both. That "right to experiment" is something small biotechs do not have, and it is itself a cost advantage.

  The key judgment: will the moat widen or narrow over the next 3-5 years?

  Within CF: slightly wider. The launch of ALYFTREK extends exclusivity and expands the range of treatable mutations, proactively reinforcing the moat through product upgrades. CF is a market Vertex has nearly monopolized, and the probability of disruption within three to five years is low.

  At the company level: the direction is uncertain, and this is the real variable. The report's central concern is exactly this: CF is effectively a single engine (still about 97.6% of product revenue in the first quarter of 2026). For the company-level moat to "widen," Vertex must prove that its playbook of "patents + expertise + cash-flow reuse" can build another wall in kidney disease, pain treatment, and gene therapy. But those new-field moats are not yet formed. CASGEVY has complex manufacturing and no cost advantage; JOURNAVX's payer-access moat is still being built (report: about 240 million people had reimbursement access in the first quarter of 2026); povetacicept's competitiveness awaits clinical proof. At the same time, friction is eroding the edges: Royalty Pharma initiated arbitration in October 2025 over ALYFTREK royalties, claiming about 8% while Vertex claims about 4%, reminding us that "moat cash flow" is not frictionless.

  For scoring, this is a question where the "CF franchise moat is very deep (near full marks), while the overall enterprise moat is strong but still has an unresolved expansion item." The honest conclusion is that today's moat is real and hard, but the scenario in which it "widens" depends on diversification that has not yet been delivered. For long-term owners, the direction of this moat still needs to be verified over the next 3-5 years through the non-CF revenue share; it cannot be assumed to widen automatically.

  Jun 10, 2026
• QIf its core business were disrupted, does it have the DNA to reinvent itself? How does it handle mistakes and bad news?5/10

  A

  Conclusion: Vertex's reinvention DNA is "moderately strong, with real evidence." It is already trying to prevent disruption by actively moving from one disease area into multiple disease areas, and its handling of R&D failures is quite candid, decisive, and unvarnished. But this needs emphasis: it has not yet gone through the life-or-death test of its core CF business being truly disrupted, so this DNA has been demonstrated more in proactive offense than in post-crisis rebirth. The implicit premise of Baillie Gifford's question is the ability to reinvent when the core is disrupted. Vertex's answer is structural rather than accidental.

  Start with the source of the reinvention DNA. Vertex is not a company sitting on a single cash cow and harvesting it passively. The report discloses 2025 R&D expense of about 3.910 billion dollars (consistent with the public statement of about 3.9 billion), nearly one-third of that year's roughly 12 billion dollars of revenue, and the company is explicitly reinvesting CF cash flow into entirely new fields such as pain treatment, kidney disease, gene/cell therapy, and type 1 diabetes. In other words, "reinvention" is something it is actively doing. The report describes its method as serial innovation: it tends to choose targets with clear causal biology, predictable experimental markers, and relatively fast registration paths, and it uses multiple candidates to reduce the damage from single-point failure. This is an institutionalized, repeatable R&D culture, not improvisation.

  More important is how it handles mistakes and bad news, which is exactly the honesty signal Baillie Gifford cares about. The report records two points, both positive:

  First, in 2025 the company decisively stopped VX-264 (a type 1 diabetes program) after efficacy did not support further development, and recorded a 379 million dollar intangible asset impairment. It did not keep an ineffective project alive to preserve a "full pipeline" narrative; it admitted the mistake, cut losses, and freed resources. I agree with the report's assessment: "this is not a flaw, but a basic attribute of the innovative-drug industry." More important, management confronted it rather than dressing it up.

  Second, it does not hide the single-engine risk. The report cites the company's 10-K, which plainly says that "substantially all net product revenues are from CF medicines." A company willing to spell out its biggest vulnerability in formal filings is usually more credible on governance honesty.

  But the boundaries of this DNA must be drawn clearly, without overstatement:

  First, proactive offense is not the same as post-crisis rebirth. Vertex's reinvention capability has so far been shown in "opening new fronts before being disrupted." It has not faced the test of core CF being pierced by a replacement therapy or patent challenge and being forced to rebuild. True "reinvention DNA" can only be fully proven in crisis, and CF's moat remains solid so far (patent moat extending to 2037). That test has not arrived.

  Second, the reinvention outcome is still unsettled. The report reminds us that the Alpine acquisition (to obtain povetacicept) is strategically reasonable, but the economic return is unknown; whether new businesses can truly take over had still not been validated at the revenue level by the first quarter of 2026 (non-CF share about 2.4%).

  Overall, as a company that actively evolves, admits mistakes and cuts losses, and is transparent about bad news, Vertex is clearly better than most defensive incumbents. This point is solid. But whether it can rise again after its core is disrupted remains "reasonable to believe, untested in battle." For long-term owners, this is reassuring, but not a dimension that deserves blind full marks.

  Jun 10, 2026
• QDoes management (especially the founder) have a long-term view and deep alignment with the company? Is it willing to sacrifice current profits for the next five to ten years?4/10

  A

  Conclusion: the claim that management has a "strong long-term view and is willing to sacrifice current profits for five to ten years out" holds up; but the claim that "interests are deeply tied to the company" needs a discount. Vertex is governed by professional managers, with alignment created through compensation and ownership requirements, not a founder-owner company with a large founder stake. Baillie Gifford prefers structures where founders hold large stakes and share risk with shareholders. By that yardstick, Vertex's governance is "institutionally sound, even excellent, but only moderately deeply aligned."

  Start with long-termism. The evidence is strong. The most persuasive proof is not what management says, but the real money it is willing to spend: the report discloses 2025 R&D expense of about 3.910 billion dollars (consistent with the public statement of about 3.9 billion), nearly one-third of that year's roughly 12 billion dollars of revenue; in 2024, it directly absorbed about 4.4 billion dollars of AIPR&D expense for the Alpine acquisition, causing a GAAP net loss of about 536 million dollars that year. A company willing to let the annual statement turn red for long-term pipeline assets is clearly not being run for quarterly EPS. The report also notes that the company prioritizes cash for R&D and external innovation M&A, puts buybacks last, and does not mainly use cash for dividends. These are capital-allocation choices that bet on five to ten years out.

  Governance design is also strong. The 2026 proxy statement, consistent with the 2025 proxy cited in the report, shows that more than 90% of NEO compensation is performance-linked; annual equity incentives are 50% PSUs + 50% RSUs; the CEO must hold shares worth 6x salary and EVPs 4x salary, and all NEOs meet the holding requirements. The company also has clawback, anti-hedging/anti-pledging policies, and explicitly does not provide 280G tax gross-ups. This package is a high standard among large pharmaceutical companies and ties executive incentives to long-term performance and share price.

  But "deep alignment" must be discounted honestly. This is the key deduction in this question. The report discloses that CEO Reshma Kewalramani owns 41,813 shares, CFO Charles Wagner owns 38,766 shares, and directors and executives together own about 584,500 shares, only about 0.2% of total shares. Using the current share price of about 443 dollars, the CEO's direct holding is worth more than 18 million dollars. That is a large personal sum, but relative to a company worth about 113 billion dollars, the absolute alignment percentage is small. This means shareholder-management alignment mainly comes from external constraints through governance and pay design, not from the endogenous motivation of a founder with "net worth tied to the company." Vertex is long past the founder-led stage and is a typical professional-manager + institutional-shareholder structure.

  From Baillie Gifford's perspective, the tradeoff is:

  • Positive: clear long-termism (willing to sacrifice current profit for pipeline assets), rational capital allocation, honest and transparent governance, and highly performance-linked incentives.
  • Negative: no founder-level large ownership stake; "deep interest alignment" comes from systems rather than personal wealth, so theoretical alignment is not as hard as with a founder who owns a large stake.
  • Neutral to cautious: the report describes capital allocation as "rational but not necessarily outstanding": buybacks look more like "returning excess cash" than aggressive repurchases during deep undervaluation, and the Alpine acquisition return is still unproven.

  Overall, this is a trustworthy management team with a sufficiently long horizon and a well-designed system. It gives a solid answer on "willingness to sacrifice current profits for the long term." But under Baillie Gifford's preference for "founder deep alignment," it is an "excellent steward," not an "owner in the same boat with you." This dimension deserves an above-average score, not a top one.

  Jun 10, 2026
• QIf it disappeared tomorrow, how much would customers miss it? Is its growth model sustainable and not dependent on harming society or regulators?6/10

  A

  Conclusion: on "indispensability," Vertex scores extremely high. If it disappeared tomorrow, most CF patients worldwide would immediately lose the de facto only effective disease-modifying therapy, and that kind of "being missed" is life-or-death. On whether its growth model is sustainable and not dependent on harming society or regulators, the answer is "basically healthy, but with real tension": it treats real diseases and has clinical value, but its high-pricing model is naturally in a long-term negotiation with payers, medical insurance systems, and political pricing. Vertex answers the first half of Baillie Gifford's implicit double test (indispensability + social/regulatory sustainability) almost perfectly; the second half needs honest friction marks.

  Start with "how much customers would miss it." This is Vertex's strongest area. CF is a fatal genetic disease, and the report shows Vertex's TRIKAFTA/KAFTRIO is a nearly monopolistic disease-modifying therapy in the field, with 2025 revenue of about 10.313 billion dollars and the CF franchise contributing about 98.5% of product revenue. It is not a consumer choice where "losing it would be inconvenient," but a hard need where "losing it could endanger life." The report also notes that CASGEVY provides a functional cure for sickle cell disease/transfusion-dependent beta thalassemia, and JOURNAVX is the first new-mechanism non-opioid pain medicine in more than 20 years. These solve real and serious unmet medical needs. In terms of customer dependence, Vertex is one of the few companies whose disappearance would create an irreplaceable loss. Its indispensability is nearly maxed out.

  But the "social/regulatory sustainability" of the growth model has to be viewed from both sides:

  The positive side: it creates real social value. Vertex's growth does not rely on addiction, attention manipulation, or regulatory arbitrage. It relies on turning untreatable diseases into treatable ones and replacing opioid-dependent pain control with a non-addictive alternative. JOURNAVX, as a non-opioid pain medicine, is even aligned with the public-health goal of alleviating the opioid crisis. That is a positive social externality. This kind of "treating disease and saving lives" growth is fundamentally sustainable and socially welcomed.

  The tension side: the high-pricing model is in a long-term contest with payment systems. The report repeatedly emphasizes that revenue is highly dependent on coverage and reimbursement by government insurance, commercial insurers, and PBMs, and the company states in its 10-K that third-party payers are becoming "increasingly stringent." Government pricing, reimbursement limits, and cost controls can all pressure revenue. The channel concentration disclosed in the report also shows strong bargaining counterparties: in 2025 McKesson accounted for 22% of gross product revenue and Accredo for 12%. This means the "price" portion of Vertex's growth must keep being scrutinized by payers and regulators. It cannot simply raise prices at will; it has to keep proving it is "worth paying for." JOURNAVX is especially typical: the report notes that as a new drug priced far above generic opioids/NSAIDs, its real-world penetration depends on whether it can translate into acceptable economics within the payment system.

  Another reminder that "moat cash flow is not frictionless": Royalty Pharma initiated arbitration in October 2025 over ALYFTREK royalties, claiming about 8% versus Vertex's claim of about 4%. This is legal friction over the distribution of economic benefits. It does not undermine the social value, but it shows that the economics of the business are being contested by multiple parties.

  Overall, under Baillie Gifford's double standard, Vertex is textbook-strong on "indispensability" (treating life-threatening disease with a nearly unique solution), and directionally right on "social sustainability" (treating real disease and not harming society). The only structural tension that requires continued vigilance is "high pricing x powerful payers/political pricing." It does not break the logic, but it will repeatedly constrain the speed of growth and the stability of profit. This is a good business that is both "needed" and "supervised."

  Jun 10, 2026
• QWhat are the unit economics of this business (gross margin, incremental returns)? Do they improve or deteriorate with scale? Where does the money it earns go?8/10

  A

  Conclusion: the unit economics are top-tier for a patented drug business: about 86% gross margin, low capital intensity, high returns on capital, and a net-cash balance sheet. Scaling makes the small-molecule CF business "better" (very low marginal cost), but for cell/gene therapies such as CASGEVY it is "not better and potentially harder" (complex manufacturing, no scale cost advantage). The money earned mainly goes into R&D and external acquisitions, with buybacks third and almost no dividends. This is the kind of business economics Baillie Gifford likes, but it needs to be analyzed by business layer rather than given a blanket full score.

  Start with the core unit economics: very attractive. The report discloses that 2025 cost of sales was about 13.8% of net product revenue, implying a gross margin of about 86.2% (consistent with public statements showing 86%+ gross margin). Based on total revenue minus total costs and expenses, operating margin was about 34.8% and net margin about 32.9%. Returns on capital are also excellent: the report roughly estimates 2025 ROE at about 22.5% and ROA at about 16.4%, and states clearly that these high returns are not built on leverage. The company has almost no interest-bearing debt and about 12.997 billion dollars of cash and marketable securities (first quarter of 2026); the returns come from patented-drug high gross margin + low capital intensity. The report notes that 2025 net property and equipment was only about 1.520 billion dollars, and maintenance capex was only about 250 million to 350 million dollars per year. That means each additional box of CF medicine sold carries very high incremental margin and requires very little incremental invested capital.

  Do unit economics improve or worsen with scale? They must be split into two layers:

  Small-molecule CF business: scale makes it better. For oral drugs such as TRIKAFTA/KAFTRIO, R&D and regulatory work are upfront fixed costs. Once approved, incremental manufacturing cost is very low, and covering one additional patient is almost pure incremental profit. Under the report's framing, the CF cash flow outside CASGEVY/JOURNAVX is precisely generated by this "high fixed, low variable" structure. Marginal returns in this area are increasing.

  Cell/gene therapy CASGEVY: scale does not bring cost advantage and may make the system harder. The report states plainly that CASGEVY "does not have a cost advantage from a manufacturing perspective; rather, it is complex," involving third-party manufacturers, Cas9 and guide RNA upstream materials, authorized treatment centers, and cross-node logistics. The scaling bottleneck is process, not demand (report: only 64 people completed infusion in 2025). The unit economics here look more like "high price, high delivery cost, slow ramp," and scale benefits are far weaker than in small molecules.

  JOURNAVX: unit economics are still to be determined. As a new-mechanism oral drug, it theoretically can enjoy the high-margin structure of small molecules over time, but it is currently early in launch and depends on payer access to convert into revenue (report: about 240 million people had reimbursement access in the first quarter of 2026). The stability of incremental returns is not yet established.

  Where does the money go? The priorities are clear and long-term oriented. The report discloses 2025 R&D expense of about 3.910 billion and SG&A of about 1.753 billion; capital allocation prioritizes R&D and external innovation acquisitions, with buybacks behind them and almost no dividends. Buybacks have increased year by year (report: about 428 million, 1.195 billion, and 2.012 billion dollars in 2023/2024/2025 respectively, plus about 345 million dollars repurchased in the first quarter of 2026). Diluted share count fell from 260.5 million in 2023 to 256.3 million in the first quarter of 2026, showing that buybacks are modestly reducing share count and offsetting equity-incentive dilution. But the report judges this more as "returning excess cash" than a decisive move during deep undervaluation. One accounting point matters: the report treats stock-based compensation (about 686 million dollars in 2025) as a real economic cost rather than "free profit," and conservatively estimates Owner Earnings at about 3.2 billion dollars on that basis. That is a more honest view of earnings quality.

  Overall, from Baillie Gifford's lens of "incremental returns + whether the money is spent well," Vertex's core business economics are top-tier (high gross margin, low capital intensity, high ROIC, net cash), and the money is mainly invested in long-term R&D and expansion, which fits a growth company. The one discount is that new businesses such as CASGEVY do not enjoy scale cost advantages and may drag down the average level of incremental returns. This is a business with an extremely strong core and heavier new margins at the edge.

  Jun 10, 2026
• QWhat conditions must all hold for it to rise fivefold in ten years? Are those conditions realistic? What expectations are embedded in today's share price?3/10

  A

  Conclusion: for Vertex to rise fivefold in ten years (about 17.5% annualized), "rapid earnings execution + no valuation contraction" must both hold, and the current share price has already prepaid a good amount of optimism, leaving little room for multiple expansion. Honest judgment: a fivefold return in ten years is an optimistic tail scenario, not the base case. It requires several new curves to all work and the market to keep paying a high premium. That is a high bar. Baillie Gifford's question has two linked premises: which conditions must all hold, and what today's price implies. For Vertex, they have to be answered together.

  Anchor today's price first. As of early June 2026, VRTX traded around 443 dollars per share, with a market value of about 113 billion dollars (the report's 2026-05-23 snapshot was 434.52 dollars and about 111.367 billion market value), and trailing PE was about 25.8x (report's LSEG metric) to about 27.6x (Macrotrends' April 2026 metric). Using the report's conservative Owner Earnings estimate (about 3.2 billion dollars), the current share price implies about 34 to 35 times earnings. That is not a cheap multiple.

  What conditions must all hold for a fivefold return in ten years? None can be missing:

  First, the CF cash cow must hold and not collapse. The report's core risk is the "single franchise": CF still accounted for about 97.6% of product revenue in the first quarter of 2026. A fivefold outcome requires CF not to be pierced over ten years by replacement therapies, patent challenges, or pricing pressure, and to complete the internal upgrade to ALYFTREK smoothly (the core patent moat extending to 2037 is a favorable condition).

  Second, at least two new curves must grow into major products. The report's optimistic case explicitly requires the company to "turn pain, kidney disease, and gene/cell therapy into at least two major products before 2030." That means JOURNAVX must grow from the report's 2025 figure of about 60 million dollars into a multi-billion-dollar product, povetacicept must become a scalable kidney-disease product line, and CASGEVY must break through manufacturing and treatment-center bottlenecks to scale (report: only 64 people completed infusion in 2025).

  Third, revenue must expand materially while margins hold. The report's neutral case implies only about 6% ten-year growth, and the optimistic case about 8%. But to support a fivefold share-price return, Owner Earnings must expand much faster than that (the report's optimistic case starts Owner Earnings at 4.5 billion, grows it at 8%, and produces a per-share value of about 485 dollars, only slightly above today).

  Fourth, the valuation multiple must not contract. This is the most overlooked and most damaging condition. The report repeatedly emphasizes that the market already assigns Vertex a significant quality premium; a fivefold return over ten years requires the market to maintain or even continue paying that high premium. If growth execution misses expectations, valuation compression alone will "consume a considerable portion of future returns," producing the report's described double hit of "earnings downgrade + multiple downgrade."

  What does today's share price imply? The report gives an intrinsic value range of 170-240 dollars in the conservative case, 280-360 dollars in the reasonable case, and 430-500 dollars in the optimistic case. The current price around 443 dollars already sits at the lower end of the optimistic range and clearly above the reasonable range. In other words, the market has already written a meaningful part of the favorable outcome of "successful non-CF diversification and scaled new curves" into today's price. The report's blunt judgment is that "if you buy today, you have already embedded a lot of future success into the price."

  Are these conditions realistic? My ruling is: possible, but not the base case. CF holding up is likely (the moat is hard), but "two or more new curves all working + valuation not contracting" is a low-probability combination that must hit simultaneously. The report's own optimistic-case annualized return is only 11%-13%, still below the about 17.5% required for a fivefold return over ten years. That itself shows that even under the company's optimistic assumptions, fivefold requires execution above expectations plus no valuation reset.

  From Baillie Gifford's "5x in ten years" perspective, the honest conclusion is that Vertex has some of the elements required for a fivefold stock (net cash, optionality, long runways), but today's price is not cheap, the margin of safety is insufficient, and treating "fivefold" as a reasonable expectation means turning an optimistic tail into the base case. The more realistic picture is an excellent company at a price already fully recognized by the market, where future returns are more likely to land in the single digits to low double digits rather than fivefold.

  Jun 10, 2026
• QWhy has the market not realized all of this yet? Is it failing to understand, looking down on it, or not looking far enough? What will be the "narrative inflection point"?3/10

  A

  Conclusion: for Vertex, the premise behind Baillie Gifford's question "why has the market not realized it yet" is partly wrong. The market has already understood it and respects it. The CF moat and quality are consensus, and the premium is the evidence. What has not really been priced is not "that it is good," but "whether non-CF diversification can work, how large it can become, and how fast." That is a matter of "not being able to see far enough" (outcomes unknown and not confirmable in advance), not "not understanding." The narrative inflection point will come when non-CF revenue moves from "rounding error" to a "verifiable second curve." This is a question where the premise needs correction.

  Start by rejecting the premise: the market does not "look down on" Vertex. The evidence is a clear premium. VRTX's current trailing PE is about 25.8x (report metric) to about 27.6x (Macrotrends, April 2026), and after comparing peers (Regeneron, Gilead, Biogen, Amgen mostly in the teens to low twenties), the report concludes VRTX trades at the high end of large-cap biopharma peers. The report's wording is apt: "today's market does not treat Vertex as a mature pharmaceutical company, but as a high-quality, net-cash, option-rich platform biotech." The market has not only understood the CF cash cow; it has also paid ahead for "optionality." So "not understanding / looking down on it" largely does not apply.

  What exactly has the market "not realized"? The answer is the final quality of the non-CF second curve. This is essentially "not being able to see far enough," because it depends on clinical, commercialization, and payment outcomes that have not yet happened:

  • No one can confirm in advance whether JOURNAVX can grow from the report's 2025 figure of about 60 million dollars, aimed at an acute pain market the company estimates at more than 80 million people per year, into a true multi-billion-dollar product (report: about 240 million people had reimbursement access in the first quarter of 2026, but penetration remains to be proven).
  • No one can confirm in advance whether CASGEVY can break through the complex bottlenecks of manufacturing/treatment centers/payment and scale meaningfully (report: only 64 people worldwide completed infusion in 2025).
  • No one can confirm in advance how many scalable product lines can emerge from povetacicept, inaxaplin, and zimislecel.

  These are not things "the market does not understand"; they are things for which there are objectively no results to price yet. The current share price is doing what the report calls "betting both sides": it enjoys the certainty of the CF cash cow while assigning some optimism to diversification (report: the current price is around the lower end of its optimistic intrinsic value range and above the reasonable range). This means the market's attitude toward the second curve is "cautiously optimistic and partly prepaid," not "ignored."

  What will become the "narrative inflection point"? The key is whether non-CF moves from "story" to a confirmed or refuted "verifiable second growth pole." Specific inflection signals include:

  Upside inflection: diversification is validated. If the company's 2026 non-CF revenue guidance of "at least 500 million dollars" is materially exceeded and the non-CF share starts to rise meaningfully year by year (currently only about 2.4%); if CASGEVY and JOURNAVX, which already contributed more than 25% of first-quarter 2026 growth, continue and accelerate; if kidney-disease pipelines such as povetacicept succeed in registration and report strong data, then the market will re-rate Vertex from "CF + options" into a "genuinely multi-platform company," and the premium will gain fundamental support.

  Downside inflection: the story is disproven. The sell signals listed in the report are also the other side of the inflection: sustained CF decline not caused by product migration, JOURNAVX revenue still stagnating after expanded coverage, CASGEVY scaling remaining far below expectations for a long time, key late-stage pipeline failures, or another large acquisition with unclear return logic. If any of these occurs, today's quality premium will unwind and trigger a repricing through "earnings downgrade + multiple downgrade."

  The honest Baillie Gifford conclusion: this is not a story where "the market has missed it and smart money can pick it up cheaply." The market has already fully priced Vertex's excellence and has even prepaid some diversification success. For long-term owners, the real opportunity window is not "the market has not realized it is good," but the one the report identifies: wait for the market to overreact to short-term R&D, reimbursement, manufacturing, litigation, or quarterly noise and push the price down to a reasonable range (the report's ideal entry point is 250-320 dollars). The substance of the narrative inflection point is the day the non-CF second curve turns "optionality" into "certainty."

  Jun 10, 2026